

CURRICULUM VITAE

INVESTIGATOR NAME Arturo Ariel Barbero
INVESTIGATOR NATIONALITY Argentina
LICENSE NUMBER MP 114835
STUDY LOCATION ADDRESS: **Centro de Investigaciones Médicas Mar del Plata**
Av. Colón 3083, 1º, 4º, 5º and 7º
floor, B7600FYK Mar del Plata. Bs. As. Argentina
Tel: 223 491-7628 / 495-6654

EDUCATION: University, date and title obtained
Dec 2003 Universidad Nacional de Cordoba, Facultad de Ciencias Médicas
Title: Physician

GRADUATE: Specialty, dates, names of institutions
Sep 2008 Specialist in Oncology. Awarded by Ministerio de Salud Republica Argentina
Dec 2008 Postgraduate in Clinical Pharmacological Research Instituto de Biología y Medicina Experimental.
Aug 2009 Specialist in Clinical Oncology Awarded by the Colegio de Medicos I District
Apr 2015 Hierarchical specialist in Oncology. Awarded by the Colegio de Médicos IX District
Apr 2015 Specialist Title Recertification
Nov 2022 Training in Good Clinical Practices NIDA

PROFESSIONAL EXPERIENCE

Current work:

Head of the Oncology Service of the C.E.D. (Centro de Estudios Digestivos), Mar del Plata. Since 2015 to present
-Head of the Oncology Service of Hospital Municipal de Ayacucho Dr. Pedro Solanet", Ayacucho, Since March 2014 to present
-Physician of the Oncology Service of the C.E.M.A (Centro de Especialidades Médicas Ambulatorias), Mar del Plata, Since April 2012 to the present.
-Coordinator of the Oncology Service at Clínica Mitre, Mar del Plata, Since 2012 to the present.
-Staff doctor of the Oncology Service of the Clínica del Niño y la Familia, Mar del Plata, Since April 2021 to the present.
-Oncologist Sub Investigator Centro de Investigaciones Médicas Mar del Plata Since Nov 2022 to Jan 2023
-Medical doctor and Principal Investigator Oncologist with an experience in Melanoma Since 2023

Previous work:

-Oncologist, Clínica Pueyrredon, Mar del Plata, Since September 2010 to August 2014.
-Oncologist, Sanatorio Belgrano, Mar del Plata, Since October 2011 to March 2018

COURSES

-Scientific work: MALIGNANT CHOROID MELANOMA: A RARE FORM OF EVOLUTION. Quality: Poster. Entity: Entity XVII International Congress of Oncology.AAOC. Buenos Aires, Argentina. 16/11/2005
-Update Conference on melanomas and sarcomas. Buenos Aires. 19/08/15

PROFESSIONAL EXPERIENCE IN CLINICAL RESEARCH

2006-Phase III Randomized, double-blind, multicenter, parallel group study to evaluate efficacy of study drug versus drug x in patients with locally advanced or metastatic (stage IIIB - IV) non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy treatment. Sub Investigator

2007- Phase III Open-label, randomized, multicenter, two-parallel group trial drug study versus drug x in patients with metastatic or locally advanced breast cancer previously treated with anthracyclines and taxanes and refractory to the most recent chemotherapy. Sub Investigator and Study Coordinator

2007- Phase III Multicenter, randomized, double-blind study of study drug in patients with metastatic colorectal cancer receiving drug x as first-line treatment. Sub-investigator and study coordinator

2008- Phase III Randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of drug x in combination with gemcitabine administered as first-line treatment to patients with unresectable, locally advanced, or pancreatic adenocarcinoma. metastatic. Assistant Investigator

2010- Phase III Multicenter, placebo-controlled, double-blind study to compare drug x with sorafenib in advanced renal cancer. Sub Investigator.

-EFC15935 AMEERA-5 Phase III Breast cancer. Since 2023 Principal Investigator

2024 -AMG20210031. Fase III. Melanoma no resecable o metastasico sin tratamiento previo. Investigador Principal

-GO42784 LIDERA Phase III Breast cancer. Since 2022 Sub Investigator/ Since 2023 Principal Investigator

-D9268C00001 TROPION-01. Phase III Unresectable Breast cancer or metastatic hormone receptor positive, HER2 negative. Since 2022. Sub Investigator/ Since 2023 Principal Investigator

-D926PC00001 TROPION-02. Phase III Locally recurrent inoperable or metastatic triple-negative breast cancer, who are not candidates for PD-1/PD-L1 inhibitor therapy. Since Jan 2023 Principal Investigator


2024 -AMG20210031. Phase III. Unresectable or Metastatic Melanoma. Principal Investigator

2024-OPI1250-301 (OPERA-01) Phase III, Estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer. Principal Investigator

2024- AMG20220083-VERBENA Phase III Resected Stage III or IV Melanoma Subjects in the Adjuvant Setting Principal Investigator

DATE: 16 - JAN - 2024

SIGNATURE:


Arturo Barbero
Esp. Oncología
M.P. 114.835